We assessed the anti-leukemic activity of a novel hydroxamate-based pan-HDAC inhibitor MAKV-8, which complied with the Lipinski’s “rule of five,” in various CML cells alone or in combination with imatinib. Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.